{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:54:36Z","timestamp":1783598076985,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.04.003","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T03:01:48Z","timestamp":1492657308000},"page":"5495-5502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Replacing antibodies with modified DNA aptamers in vaccine potency assays"],"prefix":"10.1016","volume":"35","author":[{"given":"Jeremiah J.","family":"Trausch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Shank-Retzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Verch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.003_b0005","unstructured":"FDA. Guidance for industry: potency tests for cellular and gene therapy products. Office of Communication, Outreach and Development (OCOD); 2011."},{"issue":"6","key":"10.1016\/j.vaccine.2017.04.003_b0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMra1204186","article-title":"Designing tomorrow's vaccines","volume":"368","author":"Nabel","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2017.04.003_b0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bioeng.2007.06.001","article-title":"SELEX\u2013a (r)evolutionary method to generate high-affinity nucleic acid ligands","volume":"24","author":"Stoltenburg","year":"2007","journal-title":"Biomol Eng"},{"issue":"12","key":"10.1016\/j.vaccine.2017.04.003_b0020","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2174\/1568026615666150413154038","article-title":"Outlook for aptamers after twenty five years","volume":"15","author":"Tsae","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.vaccine.2017.04.003_b0025","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bios.2014.09.026","article-title":"Aptamers as a replacement for antibodies in enzyme-linked immunosorbent assay","volume":"64","author":"Toh","year":"2015","journal-title":"Biosens Bioelectron"},{"issue":"2","key":"10.1016\/j.vaccine.2017.04.003_b0030","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.trac.2007.12.004","article-title":"Aptamer-based biosensors","volume":"27","author":"Song","year":"2008","journal-title":"Trends Anal Chem"},{"issue":"32","key":"10.1016\/j.vaccine.2017.04.003_b0035","doi-asserted-by":"crossref","first-page":"10002","DOI":"10.1073\/pnas.1502159112","article-title":"The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation","volume":"112","author":"Chen","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5152","key":"10.1016\/j.vaccine.2017.04.003_b0040","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1126\/science.7510417","article-title":"High-resolution molecular discrimination by RNA","volume":"263","author":"Jenison","year":"1994","journal-title":"Science"},{"issue":"4968","key":"10.1016\/j.vaccine.2017.04.003_b0045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"issue":"6287","key":"10.1016\/j.vaccine.2017.04.003_b0050","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.vaccine.2017.04.003_b0055","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10529-007-9629-6","article-title":"Selection of DNA aptamers against VEGF165 using a protein competitor and the aptamer blotting method","volume":"30","author":"Hasegawa","year":"2008","journal-title":"Biotech Lett"},{"issue":"12","key":"10.1016\/j.vaccine.2017.04.003_b0060","doi-asserted-by":"crossref","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.003_b0065","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1038\/mtna.2014.32","article-title":"Oligonucleotide aptamers: new tools for targeted cancer therapy","volume":"3","author":"Sun","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"10.1016\/j.vaccine.2017.04.003_b0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0163-4453(83)93645-9","article-title":"Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate","volume":"6","author":"Beuvery","year":"1983","journal-title":"J Infect"},{"issue":"27","key":"10.1016\/j.vaccine.2017.04.003_b0075","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1016\/j.vaccine.2010.04.072","article-title":"Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use","volume":"28","author":"Shinefield","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2017.04.003_b0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Broker","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2017.04.003_b0085","unstructured":"Hamborsky J, Kroger A, Wolfe C. Epidemiology and prevention of vaccine-preventable diseases, 2015."},{"issue":"12","key":"10.1016\/j.vaccine.2017.04.003_b0090","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/eji.1830251202","article-title":"Epitopes for human CD4+ cells on diphtheria toxin: structural features of sequence segments forming epitopes recognized by most subjects","volume":"25","author":"Raju","year":"1995","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.04.003_b0095","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/315324","article-title":"Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins","volume":"181","author":"Diethelm-Okita","year":"2000","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2017.04.003_b0100","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.1074\/jbc.M113.532580","article-title":"Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor","volume":"289","author":"Gupta","year":"2014","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.vaccine.2017.04.003_b0105","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1074\/jbc.M113.532697","article-title":"Crystal structure of interleukin-6 in complex with a modified nucleic acid ligand","volume":"289","author":"Gelinas","year":"2014","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.vaccine.2017.04.003_b0110","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/pmic.201300187","article-title":"Beyond antibodies: new affinity reagents to unlock the proteome","volume":"14","author":"Lollo","year":"2014","journal-title":"Proteomics"},{"issue":"2","key":"10.1016\/j.vaccine.2017.04.003_b0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0091-6749(97)70229-X","article-title":"Quantification of the major brown shrimp allergen Pen a 1 (tropomyosin) by a monoclonal antibody-based sandwich ELISA","volume":"100","author":"Jeoung","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2017.04.003_b0120","doi-asserted-by":"crossref","unstructured":"Ochsner UA, Green LS, Gold L, Janjic N. Systematic selection of modified aptamer pairs for diagnostic sandwich assays. Biotechniques 2014;56(3) [125\u2013128, 130, 132\u2013123].","DOI":"10.2144\/000114134"},{"issue":"7","key":"10.1016\/j.vaccine.2017.04.003_b0125","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.vaccine.2017.04.003_b0130","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00216-007-1346-4","article-title":"Aptamers: molecular tools for analytical applications","volume":"390","author":"Mairal","year":"2008","journal-title":"Anal Bioanal Chem"},{"issue":"15","key":"10.1016\/j.vaccine.2017.04.003_b0135","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1016\/j.molimm.2009.06.010","article-title":"Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges","volume":"46","author":"Huflejt","year":"2009","journal-title":"Mol Immunol"},{"issue":"20","key":"10.1016\/j.vaccine.2017.04.003_b0140","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2174\/138161210791792877","article-title":"Aptamer-based carbohydrate recognition","volume":"16","author":"Sun","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"26","key":"10.1016\/j.vaccine.2017.04.003_b0145","doi-asserted-by":"crossref","first-page":"E2656","DOI":"10.1073\/pnas.1401131111","article-title":"Origins of specificity and affinity in antibody-protein interactions","volume":"111","author":"Peng","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.vaccine.2017.04.003_b0150","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/clinchem\/45.9.1628","article-title":"Aptamers: an emerging class of molecules that rival antibodies in diagnostics","volume":"45","author":"Jayasena","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.vaccine.2017.04.003_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aca.2014.04.055","article-title":"Aptamer binding assays for proteins: the thrombin example\u2013a review","volume":"837","author":"Deng","year":"2014","journal-title":"Anal Chim Acta"},{"issue":"7","key":"10.1016\/j.vaccine.2017.04.003_b0160","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1021\/ac0483926","article-title":"DNA aptamer-based bioanalysis of IgE by fluorescence anisotropy","volume":"77","author":"Gokulrangan","year":"2005","journal-title":"Anal Chem"},{"issue":"9","key":"10.1016\/j.vaccine.2017.04.003_b0165","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1007\/s00216-010-4304-5","article-title":"Nucleic acid-based fluorescent probes and their analytical potential","volume":"399","author":"Juskowiak","year":"2011","journal-title":"Anal Bioanal Chem"},{"issue":"5","key":"10.1016\/j.vaccine.2017.04.003_b0170","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1365-2443.2000.00331.x","article-title":"Molecular beacon aptamer fluoresces in the presence of Tat protein of HIV-1","volume":"5","author":"Yamamoto","year":"2000","journal-title":"Genes Cells"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17304541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17304541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T22:19:18Z","timestamp":1601936358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17304541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":34,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17304541"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Replacing antibodies with modified DNA aptamers in vaccine potency assays","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}